WO2020076246A1 - Composition à base d'herbes utilisée pour une inflammation chronique et infectieuse de la prostate - Google Patents

Composition à base d'herbes utilisée pour une inflammation chronique et infectieuse de la prostate Download PDF

Info

Publication number
WO2020076246A1
WO2020076246A1 PCT/TR2018/050614 TR2018050614W WO2020076246A1 WO 2020076246 A1 WO2020076246 A1 WO 2020076246A1 TR 2018050614 W TR2018050614 W TR 2018050614W WO 2020076246 A1 WO2020076246 A1 WO 2020076246A1
Authority
WO
WIPO (PCT)
Prior art keywords
infectious
developed
herbal composition
use against
against chronic
Prior art date
Application number
PCT/TR2018/050614
Other languages
English (en)
Inventor
Natig YUSUBOV
Original Assignee
Gmg Grand Medical Ilaclari Limited Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmg Grand Medical Ilaclari Limited Sirketi filed Critical Gmg Grand Medical Ilaclari Limited Sirketi
Publication of WO2020076246A1 publication Critical patent/WO2020076246A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Definitions

  • the invention relates to the herbal and pharmaceutical composition that intends to decrease the symptoms of chronic and infectious prostate inflammation such as pain, discomfort and pollakiuria.
  • the invention also contains the production method of such composition.
  • Prostatitis is an inflammatory disease of prostate and, occasionally, effecting surrounding tissues. Prostate is a common inflamatory problem among men and it is usually seen in every 4 of 10 men who apply to a doctor due to genital or urinary problems. Found in every healthy man and necessary for reproduction, prostate gland can also get infected like any other organs of the body. Prostate infection medically known as prostatitis can also be seen in men who are young and are at a reproductive age. Unless treated at an early stage and property, prostatitis will become chronic in time highly inclined to get chronic. A part of prostate types can develop prostate infection even without bacteria. This is a condition that can appear at any age after puberty. Frequently encountered, chronic prostatitis can not be diagnosed since it has no distinct symptoms and mostly occur in conjunction with other urinary tract infections.
  • Non-bacterial chronic infection of prostate causes "chronic non-bacterial prostatitis" in men which is the infection of prostate without a cause of a particular bacteria. Prostatitis is observed in 90% of the cases.
  • Prostatitis can develop also in other organs such as urethra and bladder.
  • Prostatitis is called infectious prostatitis if associated with pathogen. This type of prostatitis appear due to bacteria (staphylococcus, pneumococcus, streptococcus), viruses (herpes), both bacteria and viruses or a specific infection (tuberculosis, ureaplasma, microplasma).
  • Antibiotic treatment which is applied as the first step is continued for 2 to 8 weeks.
  • Other treatments are non antiinflammatory steroids; immunomodulators; and combined phytopreparates following alpha-1 adrenoblockers and antibiotics.
  • Antibiotics are the first choice for all types of prostatitis. Though it is believed that the etiologies of approximately 90% of all chronic prostatitis cases, antibiotic treatment is applied to many patients. The reason for this is that the patients with negative culture respond to antibiotics treatment and that almost half of the patients from all the categories profit by quinolon treatment. A drug must highly melt in lipid and bind to serum proteins as least as possible in order for such drug to penetrate into prostate. Many types of antibiotics are not available for the treatment of prostate infections since such antibiotics are ionized in serum and ionized agents cannot permeate through prostate epithelium. The use of herbal compositions have become widespread to overcome such issues. The Turkish Patent application no.
  • the herbal composition subject to the aforementioned invention consists of epilobium parviflorum essence, ruscus aculeatus essence and distilled water.
  • Prostatonin also have herbal contents.
  • the pharmaceutical preparation called Prostatonin comprises urtica dioca and pygenium africanum herbs.
  • the indications of Prostatonin are known to have alleviated the early symptoms of prostatitis. Such drug helps patients to empty bladder better, have less frequent need for urination, decrease nocturia and normalize urination rate.
  • the purpose of the invention is to decrease the symptoms of chronic and infectious prostate inflammation such as pain, discomfort and pollakiuria using a new herbal composition subject to this invention.
  • the second purpose of the invention is to overcome the aforementioned problems that occur in the recognized technique.
  • composition subject to such invention is a product that comprising epilobium parviflorum, urtica dioca, arctostaphylos uva-ursi, avocado-soy and quercetin.
  • the formulation developed is a herbal preparation used following the surgical interventions to severe and chronic bacterial prostatitis and prostate gland.
  • Urtica dioca ensures anti-inflammatory effect and inhibits 5-alpha reductase and aromatase activities. Therefore, it suppresses testosterone and the induced increases in prostate. As a result, urtica dioca is efficient in the symptomatic treatment of lower urinary tract diseases (nocturia, polyuria, urine retention etc.).
  • Arctostaphylos uva-ursi essence can react against the most common pathogens (Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Mycobacterium smegmatis, Shigella sonnei, Proteus mirabilis and Pseudomonas aeruginosa).
  • avocado-soy is a natural herbal essence made from avocado and soy bean oil. As a supplement, it achieved to decrease the pain and the amount of non-steroidal antiinflammatory drugs (NSAID) for the patients with inflammatory diseases.
  • NSAID non-steroidal antiinflammatory drugs
  • Quercetin is a bioflavonoid that is commonly comprised in polyphenolic herbs.
  • the antioxidant and anti-inflammatory characteristics of it are certified, and the agent is known to inhibit inflammatory cytokines that play a role in prostatitis pathogenesis.
  • quercetin also bears antifungal characteristics that can react against weak antibacterial activity and prostatitis.
  • the herbal composition subject to the invention which is developed for use against chronic and infectious prostate inflammation comprising epilobium parviflorum, urtica dioca, arctostaphylos uva-ursi, avocado-soy and quercetin.
  • Another feature of the herbal composition which has been developed for use against chronic and infectious prostate inflammation is that it comprising 4-30% by weight epilobium parviflorum, 4-60% by weight urtica dioca, 2-55% by weight arctostaphylos uva-ursi, 2-49% by weight avocado-soy and 0,1-42% by weight quercetin.
  • Another feature of the herbal composition which has been developed for use against chronic and infectious prostate inflammation is that it comprising at least one excipient.
  • the aforementioned formulation comprises viscosifying as excipient.
  • the formulation of the developed herbal composition comprising 0.01-1% by weight viscosifier.
  • the viscosifier is preferably xanthan gum.
  • the aforementioned formulation comprises solubilizer as excipient.
  • the formulation of the developed herbal composition comprises 0.01-5% by weight solubilizer.
  • the invention preferably comprises polyethylene glycol (PEG) as solubilizer.
  • the developed formulation comprises preservative as excipient.
  • the formulation of the developed herbal composition comprises 0.01- 2% by weight preservative.
  • the invention preferably comprises sodium benzoate and/or potassium sorbate as preservative.
  • the developed formulation comprises acid regulator as excipient.
  • the formulation of the developed herbal composition comprises 0.01- 1% by weight acid regulator.
  • the invention preferably comprises citric acid as regulator.
  • Another feature of the developed formulation is that it comprises sweetener as excipient.
  • the formulation of the developed herbal composition comprises 0.01-2% by weight sweetener.
  • the invention contains sucralose and/or liqueur as sweetener.
  • Another feature of the developed formulation is that it comprises a herb chosen among Arecaceae, Zingiberaceae or Cucurbitaceae family.
  • Another feature of the developed herbal formulation is that it comprises a 20-45% herb by weight from Arecaceae family.
  • Saw palmetto extract from Arecaceae family was used in an application of the invention.
  • Saw palmetto extract is obtained from the fruits of a tree called by the same name. This extract is successfully used for the treatment of prostate gland enlargement and urinary tract infection.
  • Saw palmetto comprises oil acids that decreases the amount of di hydrotestosterone in prostate. These oil acids also diminish the movements of inflammatory agents and prevents prostate enlargement to a great extent.
  • Another feature of the developed herbal formulation is that it comprises a 10-65% herb by weight from Zingiberaceae family.
  • An application of the invention availed of Curcuma longa from Zingiberaceae family which is also known as turmeric. It is known to prevent intestinal polyp formation and esophageal, colon, liver, lung and prostate cancers.
  • Cucurbita pepo Another feature of the developed herbal formulation is that it comprises a 10-45% herb by weight from Cucurbitaceae family.
  • Cucurbita pepo was used in an application of the invention.
  • Cucurbita pepo is a type of summer squash. Among the recognized benefits of summer squash are increased digestion, low cholesterol levels, improved heart health and prevention of cancer.
  • Another feature of the developed herbal formulation is that it improves the treatment efficiency and shortens treatment period when used with antibiotics.
  • antibiotics and herbal drugs affect pathology differently. Antibiotics affect bacteria directly (their membranes and the size of their reproduction etc.) while herbal compositions indirectly decrease the activity of contagious process (anti inflammatory activity, activation of immunoprotective mechanisms and diuretic effect etc.).
  • the formulation in this invention is an efficient composition in consideration of the anti inflammatory and antibacterial effects that are obtained when using the drug after a prostate surgery.
  • the drug is used in combination with antibiotics considering that generally antibiotics are prescribed for such purpose after operations.
  • a production method for the herbal composition comprising;
  • Epilobium parviflorum and urtica dioica are distilled by ensuring the weight proportions specified and are transferred to fluid tanks.
  • Polyethylene glycol is added and the composition is stirred.
  • Arctostaphylos uva-ursi, avocado-soy and quercetin are added and stirred.
  • composition is bottled according to dosage forms and are stored.
  • the product in this invention can preferably be in liquid forms such as oral solution, syrup, suspension.
  • the dosage form of the product in this invention should not be limited with such examples and should also comprise all the forms that can be applied with the technique.
  • An exemplary formulation of the herbal composition of this invention is provided in Table 1. The product has been produced in suspension form by performing the aforementioned production method with the specified proportions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition à base d'herbes qui a pour but de diminuer les symptômes d'une inflammation chronique et infectieuse de la prostate telle que la douleur, la détresse et la thamurie ; et contient de l'epilobium parviflorum, de l'urtica dioca, de l'arctostaphylos uva-ursi, de l'avocat-soja et de la quercétine. La présente invention concerne également un procédé de production de cette composition
PCT/TR2018/050614 2018-10-12 2018-10-22 Composition à base d'herbes utilisée pour une inflammation chronique et infectieuse de la prostate WO2020076246A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/15185A TR201815185A2 (tr) 2018-10-12 2018-10-12 Kroni̇k ve enfeksi̇yöz prostat i̇nflamasyonunda kullanilan bi̇tki̇sel bi̇leşi̇m
TR2018/15185 2018-10-12

Publications (1)

Publication Number Publication Date
WO2020076246A1 true WO2020076246A1 (fr) 2020-04-16

Family

ID=65441034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050614 WO2020076246A1 (fr) 2018-10-12 2018-10-22 Composition à base d'herbes utilisée pour une inflammation chronique et infectieuse de la prostate

Country Status (2)

Country Link
TR (1) TR201815185A2 (fr)
WO (1) WO2020076246A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000012082A1 (it) * 2020-05-22 2021-11-22 Alpiflor S R L Composizione nutrizionale ed integratore alimentare contenente detta composizione nutrizionale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007604A1 (fr) * 1998-08-03 2000-02-17 Wheeler Ronald E Formule destinee a la prostate
WO2008030536A2 (fr) * 2006-09-07 2008-03-13 Jacquet Robert J Procédé d'utilisation d'une espèce d'epilobium dans le traitement d'un équilibre hormonal chez des animaux à sang chaud, et procédé de fabrication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007604A1 (fr) * 1998-08-03 2000-02-17 Wheeler Ronald E Formule destinee a la prostate
WO2008030536A2 (fr) * 2006-09-07 2008-03-13 Jacquet Robert J Procédé d'utilisation d'une espèce d'epilobium dans le traitement d'un équilibre hormonal chez des animaux à sang chaud, et procédé de fabrication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARYEH KEEHN ET AL: "Complementary and alternative medications for benign prostatic hyperplasia", THE CANADIAN JOURNAL OF UROLOGY, 1 October 2015 (2015-10-01), Canada, pages 18, XP055592096, Retrieved from the Internet <URL:https://www.canjurol.com/html/free-articles/JUV22I5S1F_08_DrLowe.pdf> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000012082A1 (it) * 2020-05-22 2021-11-22 Alpiflor S R L Composizione nutrizionale ed integratore alimentare contenente detta composizione nutrizionale

Also Published As

Publication number Publication date
TR201815185A2 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
Zeng et al. Protective roles of flavonoids and flavonoid-rich plant extracts against urolithiasis: A review
Doddola et al. Evaluation of Sesbania grandiflora for antiurolithiatic and antioxidant properties
Yadav et al. Herbal plants used in the treatment of urolithiasis: a review
Al‐Waili Clinical and mycological benefits of topical application of honey, olive oil and beeswax in diaper dermatitis
Nagal et al. Herbal resources with antiurolithiatic effects: a review
Lichtenstein et al. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis
Li et al. Curcumin ameliorates glyoxylate-induced calcium oxalate deposition and renal injuries in mice
Mohamed et al. Cucurbitacin E glucoside alleviates concanavalin A-induced hepatitis through enhancing SIRT1/Nrf2/HO-1 and inhibiting NF-ĸB/NLRP3 signaling pathways
Naghii et al. Antioxidant therapy prevents ethylene glycol-induced renal calcium oxalate crystal deposition in Wistar rats
Salem et al. Amelioration of gentamicin nephrotoxicity by green tea extract in uninephrectomized rats as a model of progressive renal failure
Armas et al. Efficacy of Rhizophora mangle aqueous bark extract (RMABE) in the treatment of aphthous ulcers: a pilot study
US11471501B2 (en) Pharmaceutical composition for use in the treatment of prostate pathologies
Abdel-Latif et al. Molecular mechanisms of natural honey against H. pylori infection via suppression of NF-κB and AP-1 activation in gastric epithelial cells
Majumdar et al. Potent antiulcerogenic activity of ethanol extract of leaf of Piper betle Linn by antioxidative mechanism
Bhattacharjee et al. Phytochemical and ethno-pharmacological profile of Crataeva nurvala Buch-Hum (Varuna): a review
WO2020076246A1 (fr) Composition à base d&#39;herbes utilisée pour une inflammation chronique et infectieuse de la prostate
US20010025059A1 (en) Composition and method for treating non-bacterial prostatitis
US20210244785A1 (en) Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue
Mahmoudi et al. Therapeutic effect of Achillea millefolium on the hemorrhoids; A randomized double-blind placebo-controlled clinical trial
Samarh et al. Evidence based medical use of aloe vera extracts, short review of literature
US20130337095A1 (en) Antimicrobial composition and its method of use
Bharskar Review on phytochemistry and pharmacological aspects of Pedalium murex Linn
Ji et al. Cranberry products for the prevention of catheter-associated urinary tract infections
US6521270B1 (en) Compositions comprising nitrofurantoin and uva ursi
Bhatt et al. Randomized Clinical Trial of an Ayurvedic Formulation, BV-7310 in Alcoholic Liver Disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18847258

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18847258

Country of ref document: EP

Kind code of ref document: A1